Rates and clinical correlates of treatment non-adherence in schizoaffective bipolar patients

Acta Psychiatrica Scandinavica

Volumn 125, Issue 5, 2012, Pages 412-418

  Murru, A ^a   Pacchiarotti, I ^a   Nivoli, A M A ^a   Bonnin, C M ^a   Patrizi, B ^a   Amann, B ^b,c   Vieta, E ^a   Colom, F ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c FIDMAG GERMANES HOSPITALÀRIES RESEARCH FOUNDATION   (Spain)

Author keywords

Antipsychotics; Mood stabilizers; Schizoaffective disorder; Treatment adherence

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; LITHIUM; VALPROIC ACID;

ADULT; AFFECT; ARTICLE; BIPOLAR DISORDER; DISEASE SEVERITY; DRUG USE; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; SCHIZOAFFECTIVE PSYCHOSIS; TREATMENT REFUSAL;

ADULT; BIPOLAR DISORDER; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 84859831370     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2012.01837.x     Document Type: Article

References (48)

1. Docherty JP, Fiester SJ. The therapeutic allieance and compliance with psychopharmacology. In: Hales RE, Frances AJ, eds. American Psychiatric Association Annual Review, vol. 5. Washington DC: American Psychiatric Press, 1986: pp:98-112.
2. Colom F, Vieta E, Martínez-Arán A et al. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry 2000;61:549-455.
3. Keck PE JR, Mcelroy SL, Strakowski SM et al. Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry 1996;57:292-297.
4. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007;30:437-452.
5. Cooper D, Moisan J, Grégoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry 2007;68:818-825.
6. Zygmunt A, Olfson M, Boyer CA et al. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002;159:1653-1664.
7. Colom F, Vieta E. Non-adherence in psychiatric disorders: misbehaviour or clinical feature? Acta Psychiatr Scand 2002;105:161-163.
8. ®. Washington DC: APA, 2000.
9. Benabarre A, Vieta E, Colom F et al. Bipolar disorder, schizoaffective disorder and schizophrenia: epidemiologic, clinical and prognostic differences. Eur Psychiatry 2001;16:167-172.
10. Kent S, Fogarty M, Yellowlees P. Heavy utilization of inpatient and outpatient services in a public mental health service. Psychiatr Serv 1995;46:1254-1257.
11. Haynes RB. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev, 2001;2:CD000011.
12. Lindenmayer JP, Liu-Seifert H, Kulkarni PM et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry 2009;70:990-996.
13. Ayuso-Gutierrez JL, Del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997;28:199-206.
14. Olfson M, Mechanic D, Hansell S et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216-222.
15. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999;60(Suppl 21):25-30.
16. Vieta E. Developing an individualized treatment plan for patients with schizoaffective disorder: from pharmacotherapy to psychoeducation. J Clin Psychiatry 2010;71(Suppl 2):14-19.
17. Jäger M, Becker T, Weinmann S et al. Treatment of schizoaffective disorder - a challenge for evidence-based psychiatry. Acta Psychiatr Scand 2010;121:22-32.
18. Morselli PL, Elgie R, Cesana BM. GAMIAN-Europe/BEAM survey II: cross-national analysis of unemployment, family history, treatment satisfaction and impact of the bipolar disorder on life style. Bipolar Disord 2004;6:487-497.
19. Perkins DO. Predictors of non-compliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128.
20. Gilbert PL, Harris MJ, Mcadams LA et al. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995;52:173-188.
21. Martínez-Arán A, Vieta E, Colom F et al. Cognitive dysfunctions in bipolar disorder: evidence of neuropsychological disturbances. Psychother Psychosom 2000;69:2-18.
22. Dequardo JR, Tandom R. Do atypical antipsychotic medications favourably alter the long-term course of schizophrenia? J Psychiatr Res 1998;32:229-242.
23. Martinez-Aran A, Scott J, Colom F et al. Treatment nonadherence and neurocognitive impairment in bipolar disorder. J Clin Psychiatry 2009;70:1017-1023.
24. Torrent C, Martínez-Arán A, Amann B et al. Cognitive impairment in schizoaffective disorder: a comparison with non-psychotic bipolar and healthy subjects. Acta Psychiatr Scand 2007;116:453-460.
25. Bora E, Yucel M, Pantelis C. Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study. Br J Psychiatry 2009;195:475-482.
26. Amann B, Gomar J, Ortiz J et al. Executive dysfunction and memory impairment in schizoaffective disorder: a comparison with bipolar disorder, schizophrenia and healthy controls. Psychol Med under review 2000;52:230.
27. Gonzalez-Pinto A, Mosquera F, Alonso M et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord 2006;8:618-624.
28. Colom F, Vieta E, Tacchi MJ et al. Identifying and improving non-adherence in bipolar disorders. Bipolar Disord 2005;7(Suppl 5):24-31.
29. Vieta E. Improving treatment adherence in bipolar disorder through psychoeducation. J Clin Psychiatry 2005;66(Suppl 1):24-29.
30. Lewandowski KE, Eack SM, Hogarty SS et al. Is cognitive enhancement therapy equally effective for patients with schizophrenia and schizoaffective disorder? Schizophr Res 2011;125:291-294.
31. Wiffen BD, Rabinowitz J, Fleischhacker WW et al. Insight: demographic differences and associations with 1-year outcome in schizophrenia and schizoaffective disorder. Clin Schizophr Relat Psychoses 2010;4:169-175.
32. Vieta E. Tertiarism in Psychiatry: the Barcelona 'Clinic' Bipolar Disorders Programme. Rev Psiquiatr Salud Ment (Barc.) 2011;4:1-4.
33. Vieta E. Bipolar Units and Programmes: are they really needed? World Psychiatry 2011;10:152.
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 1960;23:56-62.
35. Young RC, Biggs JT, Ziegler VE et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-435.
36. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
37. Velligan D, Sajatovic M, Valenstein M et al. Methodological challenges in psychiatric treatment adherence research. Clin Schizophr Relat Psychoses 2010;4:74-91.
38. Velligan DI, Lam YWF, Glahn DC et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 2006;32:724-742.
39. Pomykacz B, Mao M, Weiss RD et al. A review of brief medication-adherence instruments used in patients with schizophrenia and bipolar disorder. Harv Rev Psychiatry 2007;15:259-263.
40. Schooler NR, Sunakawa A, Weiden PJ. All source verification: a new tool for measuring adherence in schizophrenia. Schizophr Bull 2009;35:366.
41. Olfson M, Marcus SC, Wan GJ. Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients. Psychiatr Serv 2009;60:210-216.
42. Perkins DO, Gu H, Weiden PJ et al. Comparison of Atypicals in First Episode study group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008;69:106-113.
43. Robinson DG, Woerner MG, Alvir JM et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002;57:209-219.
44. Marneros A. The schizoaffective phenomenon: the state of the art. Acta Psychiatr Scand 2003;(Suppl 418):29-33.
45. Miklowitz DJ, George EL, Richards JA et al. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry 2003;60:904-912.
46. Kreuger KP, Felkey BG, Berger BA. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. J Am Pharm Assoc 2003;43:668-678.
47. Ascher-Svanum H, Zhu B, Faries D et al. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 2006;67:1114-1123.
48. Murru A, Pacchiarotti I, Nivoli AMA et al. What we know and what we don't know about the treatment of schizoaffective disorder. Eur Neuropsychopharmacol 2011;21:680-690.